Saturday 17 October 2026
Export NRSN’s income statement to Excel — free account
NeuroSense Therapeutics Ltd.
NRSN Healthcare Biotechnology
Insiders bought in the last twelve months.
3.07
0.10
−3.15%
Follow NRSN
| Older periods | Jun '24 | Sep '24 | Jun '25 | Jun '26 | |
|---|---|---|---|---|---|
Current Ratio |
+8 more quarters Free account |
0.46 | 0.21 | 0.71 | 0.28 |
Net Debt/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
Debt/Assets |
1.96% | 1.93% | 0.00% | 0.00% | |
Debt/Equity |
(0.02) | (0.01) | 0.00 | 0.00 | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.00 | — | 0.00 | — | |
Capex/Depreciation |
(0.27) | — | (0.62) | — | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
0.00% | — | 0.00% | — | |
Free Cash Flow per Share |
0.00 | — | 0.00 | — | |
Cash per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Shareholders Equity per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Interest Debt per Share |
0.00 | 0.00 | — | — | |
Book value per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow |
(5.75) | — | (4.00) | — | |
Working Capital |
(1.89) | (3.00) | (0.65) | (2.15) | |
Capital Expenditures |
0.00 | — | 0.00 | — | |
Net Current Asset Value |
(1.92) | (3.02) | (0.65) | (2.15) | |
| Other line items | |||||
Quick Ratio |
0.46 | 0.21 | 0.71 | 0.28 | |
Operating CF per Share |
0.00 | — | 0.00 | — | |
Capex per Share |
0.00 | — | 0.00 | — | |
Average Receivables |
0.41 | 0.36 | 0.54 | 0.48 | |
Average Payables |
1.29 | 1.15 | 1.28 | 1.56 | |
Average Assets |
4.85 | 3.19 | 2.43 | 1.17 | |
Average Common Equity |
(1.62) | (1.51) | (1.14) | (4.55) | |
Capex to Sales |
0.00 | — | 0.00 | — |
Columns are period end dates · fundamentals updated 2 Oct 2026